📇 Rhumatologue · PARIS · (75) · Mixte

M ERIC THERVET

Pourquoi vous devez consulter ce praticien

7 raisons identifiées

Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Référence presse grand public
Cité 4 fois dans les médias — pédagogie reconnue
Expérience confirmée
24 ans d'exercice en rhumatologie — recul clinique solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS (75)MixteRPPS 10000481175

EnseignementExpérience confirmée

24ans d'exercice (thèse 2002)

📊 Reconnaissance scientifique : 52/100📝 278 articles publiés🇫🇷 Publications académiques françaises (8)🎓 2 thèses dirigées

✨ Profil synthétique

IA · 19/05/2026

Le Dr M ERIC THERVET est un rhumatologue à Paris avec une production scientifique importante, comme en témoignent son h-index de 52 et ses 278 publications. Ses recherches portent principalement sur les maladies rénales et les vasculites. Il a dirigé des thèses dans le domaine de la physiopathologie et de la pharmacologie.

Expertises présumées

Vasculites
Maladies rénales
Glomérulopathies
Néphropathie diabétique
Biothérapies non-anti-TNF
Corticothérapie
Biomarqueurs en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022

📚 90 citations🎯 RCR 5.85Top 6% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Anti-Factor B Antibodies and Acute Postinfectious GN in Children

Journal of the American Society of Nephrology : JASN · 2020

📚 65 citations🎯 RCR 4.04Top 11% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Significance Statement Acute postinfectious GN, the leading cause of acute nephritis in children, associates with transient complement activation of undetermined mechanism. Its clinical features overlap considerably with those of C3 glomerulopathy, a severe chronic condition. In this retrospective study, the authors demonstrated that in more than 90% of children with acute postinfectious GN, complement overactivation results from activation of the alternative pathway of the complement system, driven by transient presence of autoantibodies targeting factor B, a component of the alternative C3 convertase. They also identified crucial antibody binding sites on factor B, including one correlated to disease severity at onset. The presence of anti-factor B antibodies was highly specific to acute postinfectious GN, suggesting that screening for these antibodies might help clinicians distinguish the disorder during its acute phase from C3 glomerulopathy. Background The pathophysiology of the leading cause of pediatric acute nephritis, acute postinfectious GN, including mechanisms of the pathognomonic transient complement activation, remains uncertain. It shares clinicopathologic features with C3 glomerulopathy, a complement-mediated glomerulopathy that, unlike acute postinfectious GN, has a poor prognosis. Methods This retrospective study investigated mechanisms of complement activation in 34 children with acute postinfectious GN and low C3 level at onset. We screened a panel of anticomplement protein autoantibodies, carried out related functional characterization, and compared results with those of 60 children from the National French Registry who had C3 glomerulopathy and persistent hypocomplementemia. Results All children with acute postinfectious GN had activation of the alternative pathway of the complement system. At onset, autoantibodies targeting factor B (a component of the alternative pathway C3 convertase) were found in a significantly higher proportion of children with the disorder versus children with hypocomplementemic C3 glomerulopathy (31 of 34 [91%] versus 4 of 28 [14%], respectively). In acute postinfectious GN, anti-factor B autoantibodies were transient and correlated with plasma C3 and soluble C5b-9 levels. We demonstrated that anti-factor B antibodies enhance alternative pathway convertase activity in vitro , confirming their pathogenic effect. We also identified crucial antibody binding sites on factor B, including one correlated to disease severity. Conclusions These findings elucidate the pathophysiologic mechanisms underlying acute postinfectious GN by identifying anti-factor B autoantibodies as contributing factors in alternative complement pathway activation. At onset of a nephritic syndrome with low C3 level, screening for anti-factor B antibodies might help guide indications for kidney biopsy to avoid misdiagnosed chronic glomerulopathy, such as C3 glomerulopathy, and to help determine therapy.

American journal of kidney diseases : the official journal of the National Kidney Foundation · 2020

📚 43 citations🎯 RCR 2.33Top 22% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M ERIC THERVET

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (4)

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal37

Vascularites3

Revue générale2

Biomarqueurs / Auto-Ac1

Biothérapies non-anti-TNF1

Case report / série1

Corticothérapie1

Essai clinique1

IA en rhumatologie1

Pédiatrie1

Recommandations1

Sclérodermie1

Datasets & protocoles partagés

Partager cette fiche